Biometric authentication for concert tickets? Following a multitude of pricing controversies in the secondary ticketing world ...

KBW analyst Meyer Shields maintained a Buy rating on Axis Capital (AXS – Research Report) today and set a price target of $110.00. The ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

AXS, AEG's ticketing and event access platform, is launching fingerprint and facial recognition technology for its mobile app ...

They will work to position Ukraine for reconstruction once the war is over. According to Jeff Gutchess of AXS LAW, they will ...

With on-device biometric authentication, AXS users can login to their accounts and access tickets using their fingerprints or ...

JMP Securities analyst Matthew Carletti reiterated a Hold rating on Axis Capital (AXS – Research Report) today. The company’s shares closed ...

Ticketing platform and services company AXS announced the launch of its new biometric authentication feature in the company's ...

AXS FTSE Vntr Cptl RetTrckr Fd earns an Above Average Process Pillar rating. Morningstar's algorithmically assigned Passive Process ratings are first formulated by comparing the historical ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

Here's why the latest SRAM RED group elevates the ride experience and justifies its top-tier positioning. Plus, we weighed ...